The Food and Drug Administration’s (FDA) user fee programs, which pay the salaries of agency staff who review drug and medical device applications, are set to expire on October 1, 2022. These include the Prescription Drug...more
With just a few short weeks left until August recess, there is no shortage of items on the congressional to-do list. The latest round of Supreme Court decisions has inspired new action within Congress to pass legislation...more
7/8/2022
/ BsUFA ,
Centers for Medicare & Medicaid Services (CMS) ,
Children's Health Insurance Program (CHIP) ,
Department of Health and Human Services (HHS) ,
Department of Labor (DOL) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
GDUFA ,
HELP ,
Infrastructure ,
Medicaid ,
Medical Device User Fee Program (MDUFA IV) ,
PDUFA ,
Proposed Legislation ,
Public Health Emergency ,
SCOTUS ,
Surprise Medical Bills ,
U.S. Treasury ,
User Fees
Here are some key health care policy headlines from the past week that you may have missed.
Congress -
Legislation and Committee Activity -
Bloomberg: Opioids Compromise Already in the Works in Congress – Congress is...more
9/27/2018
/ Acts of Congress ,
Centers for Medicare & Medicaid Services (CMS) ,
Continuing Resolution ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Gag Clauses ,
HELP ,
OMB ,
Opioid ,
Prescription Drugs ,
Proposed Rules ,
Regulatory Agenda ,
Telemedicine ,
Trump Administration
Congress is back in session after the August recess and, as expected, a flurry of activity took place. Here are some key health care policy headlines from the past week that you may have missed....more
9/13/2018
/ Acts of Congress ,
Affordable Care Act ,
Drug Pricing ,
HELP ,
HRSA ,
Opioid ,
Pharmacy Benefit Manager (PBM) ,
Primary Elections ,
Regulatory Agenda ,
Section 340B ,
Trump Administration
Foley’s Bipartisan Public Policy Team is pleased to share our Public Policy August Recess Health Care Newsletter in which we compiled the top health care policy news and legislation from this month. The House was not in...more
8/28/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Employee Retirement Income Security Act (ERISA) ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Prescription Drugs
Foley & Lardner LLP’s Bipartisan Public Policy Team is pleased to share this week’s “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation. Please note that the next...more
7/30/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
GAO ,
Health Insurance ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicare ,
Medicare Part D ,
MIPS ,
National Institute of Health (NIH) ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health Care policy news and legislation. *Please note that we...more
7/16/2018
/ Affordable Care Act ,
Appropriations Bill ,
Association Health Plans ,
Centers for Medicare & Medicaid Services (CMS) ,
DEA ,
Department of Education ,
Department of Health and Human Services (HHS) ,
Department of Labor (DOL) ,
Electronic Health Record Incentives ,
Employee Retirement Income Security Act (ERISA) ,
Food and Drug Administration (FDA) ,
Funding Opportunities ,
GAO ,
Health Insurance ,
Health Savings Accounts ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Medicare Advantage ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Proposed Legislation ,
Proposed Regulation ,
Section 340B ,
Telemedicine
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
7/2/2018
/ Appropriations Bill ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
FDA Approval ,
Food and Drug Administration (FDA) ,
Healthcare ,
Healthcare Fraud ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
New Legislation ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Section 340B ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration ,
Veterans Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/26/2018
/ Affordable Care Act ,
Agency Consolidation ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Funding ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Prescription Drugs ,
SAMHSA ,
Stark Law ,
State and Local Government ,
Trump Administration
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more
6/21/2018
/ Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Healthcare ,
HELP ,
Hospitals ,
Medicaid ,
Medicare ,
National Institute of Health (NIH) ,
Opioid ,
Pharmaceutical Industry ,
Proposed Legislation ,
Secretary of HHS ,
Senate Finance Committee ,
Substance Abuse ,
Trump Administration
Foley’s Bipartisan Public Policy Team is pleased to share our “Public Policy Health Care Newsletter” in which we compile the latest health care policy news and legislation. *Please note that we publish this newsletter only...more
6/12/2018
/ Affordable Care Act ,
Appropriations Bill ,
Centers for Medicare & Medicaid Services (CMS) ,
Cybersecurity ,
Department of Health and Human Services (HHS) ,
Federal Budget ,
Food and Drug Administration (FDA) ,
GAO ,
HELP ,
Legislative Agendas ,
Legislative Committees ,
Medicare ,
Medicare Part D ,
National Institute of Health (NIH) ,
Opioid ,
Pharmaceutical Industry ,
Prescription Drugs ,
Preventive Health Care ,
Substance Abuse ,
Trump Administration ,
Ways and Means Committee
Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly Health Care Newsletter” in which we compile the latest health care policy news and legislation.*Please note that we...more
5/21/2018
/ Affordable Care Act ,
Centers for Medicare & Medicaid Services (CMS) ,
Department of Health and Human Services (HHS) ,
Drug Pricing ,
Federal Funding ,
Food and Drug Administration (FDA) ,
Health Care Providers ,
Healthcare Reform ,
HELP ,
Legislative Agendas ,
Medicaid ,
Medicare ,
Opioid ,
Prescription Drugs ,
Section 340B ,
Trump Administration